tradingkey.logo

Grail Inc

GRAL
View Detailed Chart
100.070USD
+6.010+6.39%
Close 02/06, 16:00ETQuotes delayed by 15 min
3.62BMarket Cap
LossP/E TTM

Grail Inc

100.070
+6.010+6.39%
Intraday
1m
30m
1h
D
W
M
D

Today

+6.39%

5 Days

+2.30%

1 Month

-3.76%

6 Months

+202.51%

Year to Date

+16.92%

1 Year

+203.33%

View Detailed Chart

TradingKey Stock Score of Grail Inc

Currency: USD Updated: 2026-02-06

Key Insights

Grail Inc's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 86 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 105.00.In the medium term, the stock price is expected to trend up.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Grail Inc's Score

Industry at a Glance

Industry Ranking
86 / 392
Overall Ranking
212 / 4521
Industry
Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Media Coverage

Last 24 hours
Coverage Level

Very Low
Very High
Neutral

Grail Inc Highlights

StrengthsRisks
Grail, Inc. is a healthcare company focused on saving lives and shifting the paradigm in early cancer detection. The Company is focused on alleviating the global burden of cancer by using sequencing, population-scale clinical studies, and machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. Its targeted methylation-based platform can support the continuum of care for screening and precision oncology, including multi-cancer early detection in symptomatic patients, risk stratification, minimal residual disease detection, biomarker subtyping, treatment and recurrence monitoring. Its multi-cancer early detection test, the Galleri test, is a commercially available screening test for early detection of multiple types of cancer. The Galleri test can be used to screen for cancer before a person becomes symptomatic, when cancer may be more easily treated and potentially curable. The Galleri test can indicate the origin of the cancer.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 126.09% year-on-year.
Undervalued
The company’s latest PE is -9.39, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 25.81M shares, decreasing 20.00% quarter-over-quarter.
Held by CI Select Canadian Equity Fund
Star Investor CI Select Canadian Equity Fund holds 1.72K shares of this stock.

Analyst Rating

Based on 4 analysts
Buy
Current Rating
105.000
Target Price
+11.63%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Grail Inc News

More news coming soon, stay tuned...

Financial Indicators

EPS

Relevant data have not been disclosed by the company yet.

Total revenue

Relevant data have not been disclosed by the company yet.

Grail Inc Info

Grail, Inc. is a healthcare company focused on saving lives and shifting the paradigm in early cancer detection. The Company is focused on alleviating the global burden of cancer by using sequencing, population-scale clinical studies, and machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. Its targeted methylation-based platform can support the continuum of care for screening and precision oncology, including multi-cancer early detection in symptomatic patients, risk stratification, minimal residual disease detection, biomarker subtyping, treatment and recurrence monitoring. Its multi-cancer early detection test, the Galleri test, is a commercially available screening test for early detection of multiple types of cancer. The Galleri test can be used to screen for cancer before a person becomes symptomatic, when cancer may be more easily treated and potentially curable. The Galleri test can indicate the origin of the cancer.
Ticker SymbolGRAL
CompanyGrail Inc
CEORagusa (Robert)
Websitehttps://grail.com/
KeyAI